Asthma - Versorgungsleitlinien.de

NVL Asthma, 2. Auflage
Langfassung
Juli 2011, Version 1.3
204. North of England Evidence Based Guideline Development Project. The primary care
management of asthma in adults. Evidence based clinical practice guideline. Newcastle
upon Tyne: Univ. of Newcastle upon Tyne, Centre for Health Services Research; 1999.
(Report; 97).
205. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996;334(21):1380-8.
206. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison
GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet
1990;336(8728):1391-6.
207. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, Petermann W, Aubier M,
Schwabe G, Bengtsson T. Formoterol as relief medication in asthma: a worldwide safety
and effectiveness trial. Eur Respir J 2003;22(5):787-94.
208. Grembiale RD, Pelaia G, Naty S, Vatrella A, Tranfa CM, Marsico SA. Comparison of the
bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic
patients. Pulm Pharmacol Ther 2002;15(5):463-6.
209. Hermansen MN, Nielsen KG, Buchvald F, Jespersen JJ, Bengtsson T, Bisgaard H. Acute relief
of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent
asthma. Chest 2006;129(5):1203-9.
210. Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit
Care Med 2001;164(6):923-32.
211. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in
methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13(5):988-92.
212. Tattersfield AE, Lofdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, Ekstrom T.
Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised
trial. Lancet 2001;357(9252):257-61.
213. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter
Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual
pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
214. Gillissen A, Berdel D, Buhl R, Crieé CP, Kardos P, Magnussen H, Rabe KF, Rolke M,
Vogelmeier C, Worth H, Virchow JC. beta(2)-Sympathomimetika: Gefahren in der
Asthmatherapie? Lehren aus der SMART1-Studie. Eine Stellungnahme der Deutschen
Atemswegliga. Dtsch Med Wochenschr 2007;132(1-2):33-9.
215. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in
combination with formoterol for reliever therapy in asthma exacerbations: a randomised
controlled, double-blind study. Lancet 2006;368(9537):744-53.
216. Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of asthma.
Evidence table 4.2: ipratopium bromide. Edinburgh: 2008 [cited: 2008 Dez 04]. Available
from: http://www.sign.ac.uk/guidelines/published/support/guideline101/index.html
217. Walters EH, Walters J. Inhaled short acting beta2-agonist use in asthma: regular versus as
needed treatment (Cochrane Review). Cochrane Database Syst Rev 2001;(3).
218. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, Lee TH. Regular
inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working
Gilt nur für
Erwachsene
Gilt nur für
Kinder/Jugendliche
Allgemeine
Empfehlungen
© 2009 215